Clinical Read2026-06-12

KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)

Merck & Company Inc.MRK
Indication
Clear Cell Renal Cell Carcinoma (ccRCC)
Stage
phase6
Event
Approved